Haemophilia A
Conditions
Brief summary
This study will collect information on side effects and how well Esperoct® (turoctocog alfa pegol (N8-GP)) works during long-term treatment (prophylaxis) in males with haemophilia A. Participants in this study will get the same treatment as they would normally get, if they were not participating in the study. All visits at the clinic are done in the same way as participants are used to, when visiting their doctor. During visits at the clinic participants might be asked for some relevant tests if considered useful by the study doctor. During the visits the study doctor might ask if participants had any side effects since the last study visit. Participants will be asked to note down in their own diary the number of bleeds and how these were treated, as well as their regular prophylaxis. Participation in the study will last for about 5-7 years, depending on when participants join the study. Participants are free to leave the study at any time and for any reason. This will not affect their current and future medical care.
Interventions
Patients will be treated with commercially available N8-GP for prophylaxis and treatment of bleeding episodes according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available N8-GP has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Healthy volunteers
No
Inclusion criteria
* Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * The decision to initiate treatment with commercially available Esperoct® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study. * Male patients of all ages, according to local label, are allowed in this study * Diagnosis of severe or moderate Haemophilia A
Exclusion criteria
* Previous participation in this study. Participation is defined as having given informed consent in this study * Known or suspected hypersensitivity to N8-GP or related products * Mental incapacity, unwillingness or language barriers precluding adequate understanding and cooperation * Clinical suspicion or presence of FVIII inhibitors at time of inclusion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Adverse Events (AEs) reported during the study period | From inclusion of the patient (Visit 1) until the end of study (Visit 3), duration 5-7 years | Count of events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Serious Adverse Events (SAEs) reported during the study period | From inclusion of the patient (Visit 1) until the end of study (Visit 3), duration 5-7 years | Count of events |
Countries
Austria, Bulgaria, Croatia, Czechia, Estonia, Germany, Greece, Hungary, Italy, Lithuania, Portugal, Slovakia, Slovenia, Spain, Switzerland
Outcome results
None listed